Melanoma Inhibitory Activity Protéines (MIA)

may be involved in cartilage development [RGD, Feb 2006].. De plus, nous expédions MIA Anticorps (68) et MIA Kits (20) et beaucoup plus de produits pour cette protéine.

afficher tous les protéines Gène GeneID UniProt
MIA 8190 Q16674
MIA 81510 Q62946
MIA 12587 Q61865
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top MIA Protéines sur anticorps-enligne.fr

Showing 10 out of 27 products:

Catalogue No. Origin Source Conjugué Images Quantité Livraison Prix Détails
Escherichia coli (E. coli) Souris His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 30 to 35 Days
$5,370.21
Détails
Escherichia coli (E. coli) Humain His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 30 to 35 Days
$5,370.21
Détails
Escherichia coli (E. coli) Humain Inconjugué Validation with Western Blot 20 μg 4 to 8 Days
$319.00
Détails
Escherichia coli (E. coli) Humain His tag   50 μg 4 Days
$385.00
Détails
Escherichia coli (E. coli) Humain His tag 100 μg 13 to 16 Days
$553.85
Détails
Escherichia coli (E. coli) Rat His tag,GST tag 100 μg 15 to 18 Days
$784.00
Détails
Escherichia coli (E. coli) Humain Inconjugué   100 μg 2 to 3 Days
$695.00
Détails
Escherichia coli (E. coli) Humain His tag Validation with Western Blot 10 μg 4 to 8 Days
$394.90
Détails
HEK-293 Cells Humain Myc-DYKDDDDK Tag Validation with Western Blot 20 μg 11 Days
$888.80
Détails
Wheat germ Humain GST tag 10 μg 11 to 12 Days
$414.29
Détails

MIA Protéines protéines par origine et source

Origin Exprimée danse Conjugué
Human , ,
, ,
Rat (Rattus)

Mouse (Murine)
,

Plus protéines pour Melanoma Inhibitory Activity (MIA) partenaires d'interaction

Human Melanoma Inhibitory Activity (MIA) interaction partners

  1. the molecular basis of the interaction of MIA with the Hep II domain of fibronectin based on nuclear magnetic resonance spectroscopic binding assays.

  2. The frequency of MIA gene family expression was higher among squamous cell carcinomas than among other tumor types subjected to screening. MIA gene family staining was observed frequently in esophageal and lung cancers associated with nodal and/or distant metastasis. In cervical cancers, MIA and TANGO immunostaining also correlated with tumor progression and metastasis.

  3. Our results suggest that MIA-STOX2 signaling may be a useful diagnostic and therapeutic target in oral squamous cell carcinoma

  4. MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy

  5. real-time RT-PCR assays showed that expressions of MIA and MIA-RAB4B located 35 kb upstream of the deletion, were up-regulated in the polyps compared to the matched mucosa of the proband. MIA-RAB4B, the read-through long non-coding RNA (lncRNA), RAB4B, PIM2 and TAOK1 share common binding site of a microRNA, miR-24, in their 3'UTRs

  6. The effects of MIA/CD-RAP on transcriptional regulation in chondrocytes, through the regulation of p54(nrb) via YBX1 contributes to the understanding of chondrogenesis.

  7. data provide evidence for a critical role of SOX10 in melanoma cell invasion through the regulation of MIA and highlight its role as a therapeutic target in melanoma

  8. Focus on the quantitative analysis of the MIA protein as a prognostic tool because it has proven to be a useful serum marker for documenting disease progression of malignant melanoma. Review.

  9. Functional promoter analysis identified the transcription factor YBX1 as the mediator of MIA activation of p54(nrb) transcription.

  10. MIA protein is present in non-segmental vitiligo skin and may cause the detachment of melanocytes; its target is integrin alpha5beta1, which determines the breaking and/or weakening of connections among melanocytes and basal membrane

  11. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls.

  12. assessed the utility of melanoma inhibitory activity (MIA) serum marker in the follow up and primary diagnosis of stage III melanoma patients

  13. Further diagnostics should be initiated in uveal melanoma patients with serum MIA above 8.3ng/ml.

  14. Data suggest that plasma markers: CEACAM, ICAM-1, osteopontin, MIA, TIMP-1 and S100B particularly when assessed in combination, can be used to monitor patients for disease recurrenc.

  15. The cell-specific production rate of MIA was quantitatively proportional to the aggrecan gene expression level in the early and middle phase of cartilage chondrocyte differentiation.

  16. MIA/CD-RAP stabilizes cartilage differentiation and inhibits differentiation into bone potentially by regulating signaling processes during differentiation.

  17. pancreatic cancer patients with high intratumoral expression are antibody-negative and have shorter survival

  18. A fluorescence polarization biological assay was developed using MIA protein-binding compounds for studies of the binding properties of this protein.

  19. The assignments, solution structure, & dynamics of human MIA were determined by heteronuclear NMR methods. The structure consists of an SH3-like subdomain with N- and C-terminal extensions of about 20 amino acids each that form a novel fold.

  20. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.

Mouse (Murine) Melanoma Inhibitory Activity (MIA) interaction partners

  1. The effects of MIA/CD-RAP on transcriptional regulation in chondrocytes, through the regulation of p54(nrb) via YBX1 contributes to the understanding of chondrogenesis.

  2. Attenuated LM expressing MIA.

  3. as observed in other knockout models of molecules important for cartilage development and differentiation, viability and functional integrity is reached by remarkable molecular redundancy in MIA/CD-RAP knockout mice.

  4. The cartilage protein melanoma inhibitory activity contributes to inflammatory arthritis.

  5. Expression analysis of cartilage tissue derived from MIA-/- mice revealed strong downregulation of nuclear RNA-binding protein 54-kDa.

  6. MIA/CD-RAP stabilizes cartilage differentiation and inhibits differentiation into bone potentially by regulating signaling processes during differentiation.

  7. transcriptional mechanism by which CD-RAP expression is suppressed by IL-1 beta

  8. Cdrap/Mia is located between two housekeeping genes

  9. DNA promoter segment from -2,251 bp to -2,068 bp of the CD-RAP gene contains elements critical for gene expression. It demonstrates activation or repression of gene expression in vitro and in vivo based on cell type and content of transcription factors.

  10. A potential tumor suppressor role of Mia/Cd-rap in pituitary cells.

  11. Microarray analysis showed significant reductions in the expression of several proteins in lung misexpressing MIA.

Profil protéine MIA

Profil protéine

may be involved in cartilage development

Gene names and symbols associated with MIA

  • melanoma inhibitory activity (MIA)
  • melanoma inhibitory activity (Mia)
  • melanoma inhibitory activity (mia)
  • CD-RAP Protéine
  • Cdrap Protéine
  • mia Protéine
  • Mia1 Protéine
  • zgc:194157 Protéine

Protein level used designations for MIA

melanoma-derived growth regulatory protein , CD-RAP , melanoma inhibitory activity 1 , melanoma inhibitory activity protein , cartilage derived retinoic acid sensitive protein , cartilage-derived retinoic acid-sensitive protein , melanoma inhibitory activity/condrocyte-derived retinoic acid sensitive protein homolog (MIA/CD-RAP) , melanoma inhibitory activity-like , Melanoma-derived growth regulatory protein , melanoma-inhibitory-activity

GENE ID SPECIES
8190 Homo sapiens
81510 Rattus norvegicus
569807 Danio rerio
100286716 Salmo salar
12587 Mus musculus
280857 Bos taurus
Fournisseurs de qualité sélectionnés pour MIA Protéines (MIA)
Avez-vous cherché autre chose?